BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 10984258)

  • 1. Effects of growth hormone treatment in children with Prader-Willi syndrome.
    Lee PD
    Growth Horm IGF Res; 2000 Apr; 10 Suppl B():S75-9. PubMed ID: 10984258
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Endocrine dysfunction in Prader-Willi syndrome: a review with special reference to GH.
    Burman P; Ritzén EM; Lindgren AC
    Endocr Rev; 2001 Dec; 22(6):787-99. PubMed ID: 11739333
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The behavioral impact of growth hormone treatment for children and adolescents with Prader-Willi syndrome: a 2-year, controlled study.
    Whitman BY; Myers S; Carrel A; Allen D
    Pediatrics; 2002 Feb; 109(2):E35. PubMed ID: 11826245
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Disease management of Prader-Willi syndrome.
    Lee PD
    Expert Opin Pharmacother; 2002 Oct; 3(10):1451-9. PubMed ID: 12387691
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Benefits of long-term GH therapy in Prader-Willi syndrome: a 4-year study.
    Carrel AL; Myers SE; Whitman BY; Allen DB
    J Clin Endocrinol Metab; 2002 Apr; 87(4):1581-5. PubMed ID: 11932286
    [TBL] [Abstract][Full Text] [Related]  

  • 6. One-year results of growth hormone treatment of short stature in Prader-Willi syndrome.
    Hauffa BP
    Acta Paediatr Suppl; 1997 Nov; 423():63-5. PubMed ID: 9440907
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prader-Willi syndrome: how does growth hormone affect body composition and physical function?
    Carrel AL; Allen DB
    J Pediatr Endocrinol Metab; 2001; 14 Suppl 6():1445-51. PubMed ID: 11837498
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Somatropin therapy in adults with Prader-Willi syndrome.
    Höybye C; Thorén M
    Treat Endocrinol; 2004; 3(3):153-60. PubMed ID: 16026111
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bone mineral density in young adults with Prader-Willi syndrome: A randomized, placebo-controlled, crossover GH trial.
    Donze SH; Kuppens RJ; Bakker NE; van Alfen-van der Velden JAEM; Hokken-Koelega ACS
    Clin Endocrinol (Oxf); 2018 Jun; 88(6):806-812. PubMed ID: 29418016
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bone Health in Adults With Prader-Willi Syndrome: Clinical Recommendations Based on a Multicenter Cohort Study.
    van Abswoude DH; Pellikaan K; Rosenberg AGW; Davidse K; Coupaye M; Høybye C; Markovic TP; Grugni G; Crinò A; Caixàs A; Poitou C; Mosbah H; Weir T; van Vlimmeren LA; Rutges JPHJ; De Klerk LWL; Zillikens MC; van der Lely AJ; de Graaff LCG
    J Clin Endocrinol Metab; 2022 Dec; 108(1):59-84. PubMed ID: 36149817
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Growth hormone therapy for Prader-Willi syndrome: a critical appraisal.
    Allen DB; Carrel AL
    J Pediatr Endocrinol Metab; 2004 Sep; 17 Suppl 4():1297-306. PubMed ID: 15506076
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prader-Willi syndrome and growth hormone deficiency.
    Aycan Z; Baş VN
    J Clin Res Pediatr Endocrinol; 2014; 6(2):62-7. PubMed ID: 24932597
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Auxological and endocrine evolution of 28 children with Prader-Willi syndrome: effect of GH therapy in 14 children.
    Tauber M; Barbeau C; Jouret B; Pienkowski C; Malzac P; Moncla A; Rochiccioli P
    Horm Res; 2000; 53(6):279-87. PubMed ID: 11146368
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Glucose homeostasis in Prader-Willi syndrome and potential implications of growth hormone therapy.
    Zipf WB
    Acta Paediatr Suppl; 1999 Dec; 88(433):115-7. PubMed ID: 10626560
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Carbohydrate metabolism is not impaired after 3 years of growth hormone therapy in children with Prader-Willi syndrome.
    L'Allemand D; Eiholzer U; Schlumpf M; Torresani T; Girard J
    Horm Res; 2003; 59(5):239-48. PubMed ID: 12714788
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sustained benefits of growth hormone on body composition, fat utilization, physical strength and agility, and growth in Prader-Willi syndrome are dose-dependent.
    Carrel AL; Myers SE; Whitman BY; Allen DB
    J Pediatr Endocrinol Metab; 2001; 14(8):1097-105. PubMed ID: 11592566
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sudden death in Prader-Willi syndrome during growth hormone therapy.
    Sacco M; Di Giorgio G
    Horm Res; 2005; 63(1):29-32. PubMed ID: 15583479
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of 6 months of growth hormone treatment in young children with Prader-Willi syndrome.
    Eiholzer U; Weber R; Stutz K; Steinert H
    Acta Paediatr Suppl; 1997 Nov; 423():66-8. PubMed ID: 9401543
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Growth hormone treatment in a girl with Prader Willi syndrome.
    Pandey SN; Vaidya RA; Irani A
    Indian J Pediatr; 2003 Apr; 70(4):351-3. PubMed ID: 12793314
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Physical effects of growth hormone treatment in children with Prader-Willi syndrome.
    Myers SE; Carrel AL; Whitman BY; Allen DB
    Acta Paediatr Suppl; 1999 Dec; 88(433):112-4. PubMed ID: 10626559
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.